2015
Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome
Deckers IA, Schouten LJ, Van Neste L, van Vlodrop IJ, Soetekouw PM, Baldewijns MM, Jeschke J, Ahuja N, Herman JG, van den Brandt PA, van Engeland M. Promoter Methylation of CDO1 Identifies Clear-Cell Renal Cell Cancer Patients with Poor Survival Outcome. Clinical Cancer Research 2015, 21: 3492-3500. PMID: 25904753, PMCID: PMC4612631, DOI: 10.1158/1078-0432.ccr-14-2049.Peer-Reviewed Original ResearchConceptsCDO1 promoter methylationNetherlands Cohort StudyCysteine dioxygenase type 1Prognostic markerPromoter methylationCcRCC casesRenal cell cancer patientsProspective Netherlands Cohort StudyMultivariate modelRelative prognostic valueKaplan-Meier curvesPopulation-based seriesClear cell renal cell cancer (ccRCC) patientsCurrent prognostic markersPoor survival outcomesConfidence intervalsRelevant prognostic informationIndividual patient outcomesMultivariate HRCohort studyMethylation-specific PCR analysisCancer Genome AtlasPrognostic factorsPrognostic valuePromoter methylation status
2013
The CpG Island Methylator Phenotype: What's in a Name?
Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovée JV, French PJ, van den Brandt PA, Schouten LJ, de Meyer T, van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Engeland M. The CpG Island Methylator Phenotype: What's in a Name? Cancer Research 2013, 73: 5858-5868. PMID: 23801749, DOI: 10.1158/0008-5472.can-12-4306.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeTranslocation methylcytosine dioxygenase 2Tumor typesMethylator phenotypePrimary human astrocytesHuman neoplasiaIsocitrate dehydrogenase 1 (IDH1) mutationCpG island promoter methylationColorectal cancerOllier's diseaseAdrenocortical carcinomaProstate cancerMultiple enchondromasHuman astrocytesClinical practiceRenal cellsIDH2 mutationsCancer typesCancerDioxygenase 2Promoter methylationFunction mutationsMafucci's syndromeNeoplasiaLeukemia